

Charles L Daley

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8772279/publications.pdf>

Version: 2024-02-01

177
papers

16,923
citations

26630

56
h-index

15732

125
g-index

181
all docs

181
docs citations

181
times ranked

10483
citing authors

#	ARTICLE	IF	CITATIONS
1	Treatment of Mycobacterium abscessus Pulmonary Disease. Chest, 2022, 161, 64-75.	0.8	69
2	Consensus management recommendations for less common non-tuberculous mycobacterial pulmonary diseases. Lancet Infectious Diseases, The, 2022, 22, e178-e190.	9.1	51
3	Introducing the Nontuberculous Mycobacteria Series for CHEST. Chest, 2022, 161, 1-2.	0.8	3
4	Management of <i>Mycobacterium avium</i> complex and <i>Mycobacterium abscessus</i> pulmonary disease: therapeutic advances and emerging treatments. European Respiratory Review, 2022, 31, 210212.	7.1	18
5	Comparative safety of inhaled corticosteroids and macrolides in Medicare enrollees with bronchiectasis. ERJ Open Research, 2022, 8, 00786-2020.	2.6	6
6	Host and pathogen response to bacteriophage engineered against Mycobacterium abscessus lung infection. Cell, 2022, 185, 1860-1874.e12.	28.9	93
7	Development of Drugs for Nontuberculous Mycobacterial Disease. Chest, 2021, 159, 537-543.	0.8	9
8	Population Genomics of <i>Mycobacterium abscessus</i> from U.S. Cystic Fibrosis Care Centers. Annals of the American Thoracic Society, 2021, 18, 1960-1969.	3.2	42
9	“One-Two Punch”: Synergistic β -Lactam Combinations for <i>Mycobacterium abscessus</i> and Target Redundancy in the Inhibition of Peptidoglycan Synthesis Enzymes. Clinical Infectious Diseases, 2021, 73, 1532-1536.	5.8	15
10	A Molecular-Beacon-Based Multiplex Real-Time PCR Assay To Distinguish Mycobacterium abscessus Subspecies and Determine Macrolide Susceptibility. Journal of Clinical Microbiology, 2021, 59, e0045521.	3.9	11
11	Genomic characterization of sporadic isolates of the dominant clone of Mycobacterium abscessus subspecies massiliense. Scientific Reports, 2021, 11, 15336.	3.3	11
12	Outcomes of Inhaled Amikacin-Containing Multidrug Regimens for Mycobacterium abscessus Pulmonary Disease. Chest, 2021, 160, 436-445.	0.8	13
13	Nontuberculous mycobacteria in cystic fibrosis. Current Opinion in Pulmonary Medicine, 2021, 27, 586-592.	2.6	12
14	Pharmacokinetics of oral antimycobacterials and dosing guidance for Mycobacterium avium complex treatment in cystic fibrosis. Journal of Cystic Fibrosis, 2021, 20, 772-778.	0.7	6
15	Nontuberculous mycobacterial lung disease caused by <i>Mycobacterium avium</i> complex - disease burden, unmet needs, and advances in treatment developments. Expert Review of Respiratory Medicine, 2021, 15, 1387-1401.	2.5	21
16	Prognostic factors associated with long-term mortality in 1445 patients with nontuberculous mycobacterial pulmonary disease: a 15-year follow-up study. European Respiratory Journal, 2020, 55, 1900798.	6.7	89
17	Long-term follow-up of post-cardiac surgery Mycobacterium chimaera infections: A 5-center case series. Journal of Infection, 2020, 80, 197-203.	3.3	6
18	Summary for Clinicians: 2020 Clinical Practice Guideline Summary for the Treatment of Nontuberculous Mycobacterial Pulmonary Disease. Annals of the American Thoracic Society, 2020, 17, 1033-1039.	3.2	14

#	ARTICLE	IF	CITATIONS
19	Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline. <i>Clinical Infectious Diseases</i> , 2020, 71, 905-913.	5.8	357
20	<i>Mycobacterium avium</i> Complex: Addressing Gaps in Diagnosis and Management. <i>Journal of Infectious Diseases</i> , 2020, 222, S199-S211.	4.0	34
21	Serial sputum induction in nontuberculous mycobacterial pulmonary disease. <i>European Respiratory Journal</i> , 2020, 55, 1902196.	6.7	0
22	Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline. <i>European Respiratory Journal</i> , 2020, 56, 2000535.	6.7	336
23	Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline. <i>Clinical Infectious Diseases</i> , 2020, 71, e1-e36.	5.8	367
24	miRNA Expression Profiles and Potential as Biomarkers in Nontuberculous Mycobacterial Pulmonary Disease. <i>Scientific Reports</i> , 2020, 10, 3178.	3.3	19
25	Nontuberculosis Mycobacterial Disease. , 2019, , 498-506.e4.		0
26	Nontuberculous Mycobacterial Disease in Transplant Recipients. , 2019, , 503-517.		0
27	Managing antibiotic resistance in nontuberculous mycobacterial pulmonary disease: challenges and new approaches. <i>Expert Review of Respiratory Medicine</i> , 2019, 13, 851-861.	2.5	14
28	Efficacy and safety of tigecycline for <i>Mycobacterium abscessus</i> disease. <i>Respiratory Medicine</i> , 2019, 158, 89-91.	2.9	19
29	GenoType NTM-DR Performance Evaluation for Identification of <i>Mycobacterium avium</i> Complex and <i>Mycobacterium abscessus</i> and Determination of Clarithromycin and Amikacin Resistance. <i>Journal of Clinical Microbiology</i> , 2019, 57, .	3.9	33
30	<i>In Vitro</i> Activity of Bedaquiline and Delamanid against Nontuberculous Mycobacteria, Including Macrolide-Resistant Clinical Isolates. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	44
31	Comparative risks of chronic inhaled corticosteroids and macrolides for bronchiectasis. <i>European Respiratory Journal</i> , 2019, 54, 1801896.	6.7	31
32	<i>Mycobacterium abscessus</i> pulmonary disease: individual patient data meta-analysis. <i>European Respiratory Journal</i> , 2019, 54, 1801991.	6.7	140
33	Species Distribution and Macrolide Susceptibility of <i>Mycobacterium fortuitum</i> Complex Clinical Isolates. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	11
34	Unresolved issues in treatment outcome definitions for nontuberculous mycobacterial pulmonary disease. <i>European Respiratory Journal</i> , 2019, 53, 1801636.	6.7	6
35	Similar characteristics of nontuberculous mycobacterial pulmonary disease in men and women. <i>European Respiratory Journal</i> , 2019, 54, 1900252.	6.7	8
36	Long-term natural history of non-cavitary nodular bronchiectatic nontuberculous mycobacterial pulmonary disease. <i>Respiratory Medicine</i> , 2019, 151, 1-7.	2.9	38

#	ARTICLE	IF	CITATIONS
37	Treatment with a macrolide-containing regimen for <i>Mycobacterium kansasii</i> pulmonary disease. <i>Respiratory Medicine</i> , 2019, 148, 37-42.	2.9	12
38	Genomic Analysis of Cardiac Surgery-Associated <i>Mycobacterium chimaera</i> Infections, United States. <i>Emerging Infectious Diseases</i> , 2019, 25, 559-563.	4.3	25
39	Same meat, different gravy: ignore the new names of mycobacteria. <i>European Respiratory Journal</i> , 2019, 54, 1900795.	6.7	54
40	Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019, 200, e93-e142.	5.6	282
41	Nontuberculosis mycobacteria infections: would there be pharmacodynamics without pharmacokinetics?. <i>European Respiratory Journal</i> , 2019, 54, 1901806.	6.7	0
42	Tuberculosis. <i>Clinics in Chest Medicine</i> , 2019, 40, xi.	2.1	1
43	Treatment of <i>Mycobacterium avium</i> Complex Pulmonary Disease. <i>Tuberculosis and Respiratory Diseases</i> , 2019, 82, 15.	1.8	80
44	<i>Mycobacterium chimaera</i> Infections Related to the Heater-Cooler Unit Outbreak: A Guide to Diagnosis and Management. <i>Clinical Infectious Diseases</i> , 2019, 68, 1244-1250.	5.8	34
45	The Global Fight Against Tuberculosis. <i>Thoracic Surgery Clinics</i> , 2019, 29, 19-25.	1.0	45
46	Advancing Translational Science for Pulmonary Nontuberculous Mycobacterial Infections. A Road Map for Research. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019, 199, 947-951.	5.6	53
47	Nontuberculous Mycobacterial Infections in Cystic Fibrosis. <i>Thoracic Surgery Clinics</i> , 2019, 29, 95-108.	1.0	55
48	Genetic mutations in linezolid-resistant <i>Mycobacterium avium</i> complex and <i>Mycobacterium abscessus</i> clinical isolates. <i>Diagnostic Microbiology and Infectious Disease</i> , 2019, 94, 38-40.	1.8	10
49	<i>Mycobacterium avium</i> Complex Disease. <i>Respiratory Medicine</i> , 2019, , 301-323.	0.1	1
50	The Clinical Features of Bronchiectasis Associated with Alpha-1 Antitrypsin Deficiency, Common Variable Immunodeficiency and Primary Ciliary Dyskinesia--Results from the U.S. Bronchiectasis Research Registry. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla)</i> , 2019, 6, 145-153.	0.7	21
51	Nontuberculous Mycobacterial Musculoskeletal Infection Cases from a Tertiary Referral Center, Colorado, USA. <i>Emerging Infectious Diseases</i> , 2019, 25, 1075-1083.	4.3	17
52	Mycobacterial biomaterials and resources for researchers. <i>Pathogens and Disease</i> , 2018, 76, .	2.0	14
53	Amikacin Inhalation as Salvage Therapy for Refractory Nontuberculous Mycobacterial Lung Disease. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	41
54	The Prevalence and Significance of <i>Staphylococcus aureus</i> in Patients with Non-Cystic Fibrosis Bronchiectasis. <i>Annals of the American Thoracic Society</i> , 2018, 15, 365-370.	3.2	36

#	ARTICLE	IF	CITATIONS
55	Treatment outcomes of macrolide-susceptible <i>Mycobacterium abscessus</i> lung disease. <i>Diagnostic Microbiology and Infectious Disease</i> , 2018, 90, 293-295.	1.8	28
56	Treatment outcome definitions in nontuberculous mycobacterial pulmonary disease: an NTM-NET consensus statement. <i>European Respiratory Journal</i> , 2018, 51, 1800170.	6.7	159
57	A Woman with a 15-Year History of Bronchiectasis and Recurrent Nontuberculous <i>Mycobacterium</i> Pulmonary Disease. <i>Annals of the American Thoracic Society</i> , 2018, 15, 380-382.	3.2	1
58	Intermittent Antibiotic Therapy for Recurrent Nodular Bronchiectatic <i>Mycobacterium avium</i> Complex Lung Disease. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	15
59	ALIS (Amikacin Liposome Inhalation Suspension): The Beginning of a Wonderland?. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 198, 1473-1475.	5.6	6
60	Characteristics and Health-care Utilization History of Patients With Bronchiectasis in US Medicare Enrollees With Prescription Drug Plans, 2006 to 2014. <i>Chest</i> , 2018, 154, 1311-1320.	0.8	57
61	Mutations in <i>gyrA</i> and <i>gyrB</i> in Moxifloxacin-Resistant <i>Mycobacterium avium</i> Complex and <i>Mycobacterium abscessus</i> Complex Clinical Isolates. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	18
62	Management of Multidrug-Resistant Tuberculosis. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2018, 39, 310-324.	2.1	32
63	US Patient-Centered Research Priorities and Roadmap for Bronchiectasis. <i>Chest</i> , 2018, 154, 1016-1023.	0.8	14
64	Nontuberculous Mycobacterial Lung Diseases Caused by Mixed Infection with <i>Mycobacterium avium</i> Complex and <i>Mycobacterium abscessus</i> Complex. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	24
65	Development of Macrolide Resistance and Reinfection in Refractory <i>Mycobacterium avium</i> Complex Lung Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 198, 1322-1330.	5.6	46
66	<i>Mycobacterium avium</i> Complex Disease. <i>Microbiology Spectrum</i> , 2017, 5, .	3.0	87
67	Pharmacotherapy for Non-Cystic Fibrosis Bronchiectasis. <i>Chest</i> , 2017, 152, 1120-1127.	0.8	36
68	Safety and Effectiveness of Clofazimine for Primary and Refractory Nontuberculous Mycobacterial Infection. <i>Chest</i> , 2017, 152, 800-809.	0.8	115
69	Frequency of untreated hypogammaglobulinemia in bronchiectasis. <i>Annals of Allergy, Asthma and Immunology</i> , 2017, 119, 83-85.	1.0	4
70	Clofazimine-Containing Regimen for the Treatment of <i>Mycobacterium abscessus</i> Lung Disease. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	86
71	Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children. <i>Clinical Infectious Diseases</i> , 2017, 64, e1-e33.	5.8	501
72	Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children. <i>Clinical Infectious Diseases</i> , 2017, 64, 111-115.	5.8	492

#	ARTICLE	IF	CITATIONS
73	Outcomes of <i>Mycobacterium avium</i> complex lung disease based on clinical phenotype. <i>European Respiratory Journal</i> , 2017, 50, 1602503.	6.7	154
74	Mycobacterial Characteristics and Treatment Outcomes in <i>Mycobacterium abscessus</i> Lung Disease. <i>Clinical Infectious Diseases</i> , 2017, 64, 309-316.	5.8	169
75	Randomized Trial of Liposomal Amikacin for Inhalation in Nontuberculous Mycobacterial Lung Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 195, 814-823.	5.6	212
76	Adult Patients With Bronchiectasis. <i>Chest</i> , 2017, 151, 982-992.	0.8	282
77	Clinical Characteristics and Treatment Outcomes of Patients with Macrolide-Resistant <i>Mycobacterium massiliense</i> Lung Disease. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	27
78	<i>Mycobacterium tuberculosis</i> Infection among Asian Elephants in Captivity. <i>Emerging Infectious Diseases</i> , 2017, 23, 513-516.	4.3	10
79	Clinical Characteristics and Treatment Outcomes of Patients with Acquired Macrolide-Resistant <i>Mycobacterium abscessus</i> Lung Disease. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	44
80	Diagnosis and Treatment of Nontuberculous Mycobacterial Lung Disease: Clinicians' Perspectives. <i>Tuberculosis and Respiratory Diseases</i> , 2016, 79, 74.	1.8	172
81	Programmatic Management of Drug-Resistant Tuberculosis: An Updated Research Agenda. <i>PLoS ONE</i> , 2016, 11, e0155968.	2.5	22
82	<i>Mycobacterium chimaera</i> Outbreak Response: Experience From Four United States Healthcare Systems. <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.9	6
83	Improvement in Quality of Life after Therapy for <i>Mycobacterium abscessus</i> Group Lung Infection. A Prospective Cohort Study. <i>Annals of the American Thoracic Society</i> , 2016, 13, 40-48.	3.2	45
84	Oral Macrolide Therapy Following Short-term Combination Antibiotic Treatment of <i>Mycobacterium massiliense</i> Lung Disease. <i>Chest</i> , 2016, 150, 1211-1221.	0.8	48
85	Screening for Latent Tuberculosis Infection. <i>JAMA Internal Medicine</i> , 2016, 176, 1439.	5.1	3
86	Peak Plasma Concentration of Azithromycin and Treatment Responses in <i>Mycobacterium avium</i> Complex Lung Disease. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 6076-6083.	3.2	43
87	Clinical Characteristics, Treatment Outcomes, and Resistance Mutations Associated with Macrolide-Resistant <i>Mycobacterium avium</i> Complex Lung Disease. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 6758-6765.	3.2	90
88	Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. <i>Clinical Infectious Diseases</i> , 2016, 63, e147-e195.	5.8	916
89	Patient-Centered Research Priorities for Pulmonary Nontuberculous Mycobacteria (NTM) Infection. An NTM Research Consortium Workshop Report. <i>Annals of the American Thoracic Society</i> , 2016, 13, S379-S384.	3.2	58
90	US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis: executive summary. <i>Thorax</i> , 2016, 71, 88-90.	5.6	274

#	ARTICLE	IF	CITATIONS
91	Pharmacokinetics and Dosing of Levofloxacin in Children Treated for Active or Latent Multidrug-resistant Tuberculosis, Federated States of Micronesia and Republic of the Marshall Islands. <i>Pediatric Infectious Disease Journal</i> , 2016, 35, 414-421.	2.0	26
92	Lung Function Decline According to Clinical Course in Nontuberculous Mycobacterial Lung Disease. <i>Chest</i> , 2016, 150, 1222-1232.	0.8	42
93	US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis. <i>Thorax</i> , 2016, 71, i1-i22.	5.6	348
94	Mycobacterial Lung Disease Complicating HIV Infection. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2016, 37, 230-242.	2.1	8
95	Nontuberculous Mycobacterial Infections in Cystic Fibrosis. <i>Clinics in Chest Medicine</i> , 2016, 37, 83-96.	2.1	65
96	Blood Transcriptional Biomarkers for Active Tuberculosis among Patients in the United States: a Case-Control Study with Systematic Cross-Classifer Evaluation. <i>Journal of Clinical Microbiology</i> , 2016, 54, 274-282.	3.9	55
97	Nontuberculous Mycobacterial Infections. , 2016, , 629-645.e6.		3
98	<i>Notes from the Field</i> : <i>Mycobacterium chimaera</i> Contamination of Heater-Cooler Devices Used in Cardiac Surgery—United States. <i>Morbidity and Mortality Weekly Report</i> , 2016, 65, 1117-1118.	15.1	98
99	The tolerability of linezolid in the treatment of nontuberculous mycobacterial disease. <i>European Respiratory Journal</i> , 2015, 45, 1177-1179.	6.7	62
100	Nontuberculous Mycobacteria. <i>Clinics in Chest Medicine</i> , 2015, 36, xi-xii.	2.1	5
101	Transcriptional Adaptation of Drug-tolerant <i>Mycobacterium tuberculosis</i> During Treatment of Human Tuberculosis. <i>Journal of Infectious Diseases</i> , 2015, 212, 990-998.	4.0	82
102	Intermittent Antibiotic Therapy for Nodular Bronchiectatic <i>Mycobacterium avium</i> Complex Lung Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015, 191, 96-103.	5.6	134
103	Response to Switch from Intermittent Therapy to Daily Therapy for Refractory Nodular Bronchiectatic <i>Mycobacterium avium</i> Complex Lung Disease. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 4994-4996.	3.2	17
104	Non-tuberculous mycobacterial infections at San Francisco General Hospital. <i>Clinical Respiratory Journal</i> , 2015, 9, 436-442.	1.6	8
105	Interferon- γ Release Assays and Tuberculin Skin Testing for Diagnosis of Latent Tuberculosis Infection in Healthcare Workers in the United States. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2014, 189, 77-87.	5.6	182
106	Genome Sequencing of <i>Mycobacterium abscessus</i> Isolates from Patients in the United States and Comparisons to Globally Diverse Clinical Strains. <i>Journal of Clinical Microbiology</i> , 2014, 52, 3573-3582.	3.9	64
107	Treatment of Pulmonary Nontuberculous Mycobacterial Infections: Many Questions Remain. <i>Annals of the American Thoracic Society</i> , 2014, 11, 96-97.	3.2	13
108	Clinical Significance of a First Positive Nontuberculous Mycobacteria Culture in Cystic Fibrosis. <i>Annals of the American Thoracic Society</i> , 2014, 11, 36-44.	3.2	102

#	ARTICLE	IF	CITATIONS
109	Interferon-Gamma Release Assays. Clinics in Laboratory Medicine, 2014, 34, 337-349.	1.4	14
110	Infections in "Noninfectious" Lung Diseases. Annals of the American Thoracic Society, 2014, 11, S221-S226.	3.2	8
111	Editorial Commentary: Treatment for Multidrug-Resistant Tuberculosis: It's Worse Than We Thought!. Clinical Infectious Diseases, 2014, 59, 1064-1065.	5.8	9
112	Linezolid for multidrug-resistant tuberculosis " Authors' reply. Lancet Infectious Diseases, The, 2013, 13, 16-17.	9.1	3
113	The geographic diversity of nontuberculous mycobacteria isolated from pulmonary samples: an NTM-NET collaborative study. European Respiratory Journal, 2013, 42, 1604-1613.	6.7	683
114	Management of Multidrug Resistant Tuberculosis. Seminars in Respiratory and Critical Care Medicine, 2013, 34, 044-059.	2.1	34
115	Serodiagnosis of <i>Mycobacterium avium</i> complex pulmonary disease in the USA. European Respiratory Journal, 2013, 42, 454-460.	6.7	43
116	Mycobacterial Infections. Seminars in Respiratory and Critical Care Medicine, 2013, 34, 001-002.	2.1	9
117	The Genome Sequence of "Mycobacterium massiliense"™ Strain CIP 108297 Suggests the Independent Taxonomic Status of the Mycobacterium abscessus Complex at the Subspecies Level. PLoS ONE, 2013, 8, e81560.	2.5	54
118	You can't always get what you want, but if you try sometimes (with two tests" TST and IGRA" for Tj ETQq0 0 0 rgBT /Overlock 10 T	0.9	64
119	Mycobacterium Avium Complex and Lung Cancer: Chicken or Egg? Both?. Journal of Thoracic Oncology, 2012, 7, 1329-1330.	1.1	12
120	<i>In Vitro</i> Synergy between Clofazimine and Amikacin in Treatment of Nontuberculous Mycobacterial Disease. Antimicrobial Agents and Chemotherapy, 2012, 56, 6324-6327.	3.2	146
121	Linezolid for multidrug-resistant tuberculosis. Lancet Infectious Diseases, The, 2012, 12, 502-503.	9.1	8
122	Pulmonary Resection and Lung Transplantation for Bronchiectasis. Clinics in Chest Medicine, 2012, 33, 387-396.	2.1	6
123	Tuberculosis and Nontuberculous Mycobacterial Infections. , 2012, , 383-405.		2
124	Macrolide Treatment for <i>Mycobacterium abscessus</i> and <i>Mycobacterium massiliense</i> Infection and Inducible Resistance. American Journal of Respiratory and Critical Care Medicine, 2012, 186, 917-925.	5.6	179
125	Drug susceptibility testing and pharmacokinetics question current treatment regimens in <i>Mycobacterium simiae</i> complex disease. International Journal of Antimicrobial Agents, 2012, 39, 173-176.	2.5	67
126	The Pharmacokinetics and Pharmacodynamics of Pulmonary <i>Mycobacterium avium</i> Complex Disease Treatment. American Journal of Respiratory and Critical Care Medicine, 2012, 186, 559-565.	5.6	175

#	ARTICLE	IF	CITATIONS
127	Are phylogenetic position, virulence, drug susceptibility and in vivo response to treatment in mycobacteria interrelated?. <i>Infection, Genetics and Evolution</i> , 2012, 12, 832-837.	2.3	33
128	Translating basic science insight into public health action for multidrug- and extensively drug-resistant tuberculosis. <i>Respirology</i> , 2012, 17, 772-791.	2.3	14
129	Management of adverse drug events in TB therapy. , 2012, , 167-193.		2
130	Factors associated with mortality in patients with drug-susceptible pulmonary tuberculosis. <i>BMC Infectious Diseases</i> , 2011, 11, 1.	2.9	204
131	Clinical Significance of Differentiation of <i>Mycobacterium massiliense</i> from <i>Mycobacterium abscessus</i> . <i>American Journal of Respiratory and Critical Care Medicine</i> , 2011, 183, 405-410.	5.6	464
132	Clinical and Microbiologic Outcomes in Patients Receiving Treatment for <i>Mycobacterium abscessus</i> Pulmonary Disease. <i>Clinical Infectious Diseases</i> , 2011, 52, 565-571.	5.8	343
133	Multiple Cytokines Are Released When Blood from Patients with Tuberculosis Is Stimulated with <i>Mycobacterium tuberculosis</i> Antigens. <i>PLoS ONE</i> , 2011, 6, e26545.	2.5	68
134	Serodiagnosis Of <i>Mycobacterium Avium</i> Complex Pulmonary Disease In The United States. , 2010, , .		0
135	Update in Tuberculosis 2009. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2010, 181, 550-555.	5.6	11
136	Effects of Gender and Age at Diagnosis on Disease Progression in Long-term Survivors of Cystic Fibrosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2010, 182, 614-626.	5.6	105
137	Nontuberculous Mycobacterial Infections. , 2010, , 793-810.		1
138	Other mycobacteria causing human disease. , 2009, , 60-74.		0
139	Road ahead to respiratory health: Experts chart future research directions. <i>Respirology</i> , 2009, 14, 625-636.	2.3	12
140	Nontuberculous mycobacterial disease in transplant recipients: early diagnosis and treatment. <i>Current Opinion in Organ Transplantation</i> , 2009, 14, 619-624.	1.6	32
141	Pandemic Influenza: Implications for Programs Controlling for HIV Infection, Tuberculosis, and Chronic Viral Hepatitis. <i>American Journal of Public Health</i> , 2009, 99, S333-S339.	2.7	12
142	Nontuberculous Mycobacterial Infections. , 2009, , 879-895.		1
143	IL-24 modulates IFN- γ expression in patients with tuberculosis. <i>Immunology Letters</i> , 2008, 117, 57-62.	2.5	17
144	Diagnosis and Treatment of Infections due to <i>Mycobacterium avium</i> Complex. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2008, 29, 569-576.	2.1	71

#	ARTICLE	IF	CITATIONS
145	A novel assay for screening patients for latent tuberculosis infection prior to anti-TNF therapy. <i>Nature Clinical Practice Rheumatology</i> , 2008, 4, 456-457.	3.2	3
146	Detailed Analysis of the Radiographic Presentation of <i>Mycobacterium kansasii</i> Lung Disease in Patients With HIV Infection. <i>Chest</i> , 2008, 133, 875-880.	0.8	27
147	Tuberculosis and Nontuberculous Mycobacterial Infections. , 2008, , 385-408.		0
148	Treatment Outcomes of Patients with HIV and Tuberculosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2007, 175, 1199-1206.	5.6	136
149	Moxifloxacin versus Ethambutol in the First 2 Months of Treatment for Pulmonary Tuberculosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2006, 174, 331-338.	5.6	277
150	Factors Related to Response to Intermittent Treatment of <i>Mycobacterium avium</i> Complex Lung Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2006, 173, 1283-1289.	5.6	162
151	Prevention of tuberculosis in HIV-infected patients. <i>Current Opinion in Infectious Diseases</i> , 2006, 19, 189-193.	3.1	12
152	Hypersensitivity Pneumonitis Reaction to <i>Mycobacterium avium</i> in Household Water. <i>Chest</i> , 2005, 127, 664-671.	0.8	151
153	Reply to Böttger et al.. <i>Journal of Infectious Diseases</i> , 2005, 191, 824-824.	4.0	0
154	Molecular Epidemiology: A Tool for Understanding Control of Tuberculosis Transmission. <i>Clinics in Chest Medicine</i> , 2005, 26, 217-231.	2.1	22
155	Potential Public Health Impact of New Tuberculosis Vaccines. <i>Emerging Infectious Diseases</i> , 2004, 10, 1529-1535.	4.3	62
156	Tuberculosis Contact Investigations. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2004, 169, 779-781.	5.6	11
157	Mortality Prediction in Pulmonary <i>Mycobacterium kansasii</i> Infection and Human Immunodeficiency Virus. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2004, 170, 793-798.	5.6	32
158	Tuberculosis Transmission Based on Molecular Epidemiologic Research. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2004, 25, 297-306.	2.1	7
159	A Molecular Epidemiological Assessment of Extrapulmonary Tuberculosis in San Francisco. <i>Clinical Infectious Diseases</i> , 2004, 38, 25-31.	5.8	72
160	The Molecular Epidemiology of Tuberculosis. , 2004, , 57-74.		1
161	A Systematic Review of the Clinical Significance of Pulmonary <i>Mycobacterium kansasii</i> Isolates in HIV Infection. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2004, 36, 883-889.	2.1	31
162	New Tuberculosis Vaccines May Have Serious Public Health Impact. <i>Emergency Medicine News</i> , 2004, 26, 67-68.	0.0	0

#	ARTICLE	IF	CITATIONS
163	American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America. American Journal of Respiratory and Critical Care Medicine, 2003, 167, 603-662.	5.6	1,828
164	Effect of Drug Resistance on the Generation of Secondary Cases of Tuberculosis. Journal of Infectious Diseases, 2003, 188, 1878-1884.	4.0	93
165	Rifampin and Pyrazinamide for Treatment of Latent Tuberculosis Infection. American Journal of Respiratory and Critical Care Medicine, 2003, 167, 809-810.	5.6	40
166	Transmission of Multidrug-Resistant Tuberculosis. American Journal of Respiratory and Critical Care Medicine, 2002, 165, 742-743.	5.6	8
167	Epidemiology of human pulmonary infection with mycobacteria nontuberculous. Clinics in Chest Medicine, 2002, 23, 553-567.	2.1	344
168	Pulmonary disease caused by rapidly growing mycobacteria. Clinics in Chest Medicine, 2002, 23, 623-632.	2.1	121
169	Early Therapy for Latent Tuberculosis Infection. American Journal of Epidemiology, 2001, 153, 381-385.	3.4	97
170	Preventing Tuberculosis among HIV-Infected Persons: A Survey of Physicians' Knowledge and Practices. Preventive Medicine, 1999, 28, 437-444.	3.4	13
171	MULTIPLE DRUG-RESISTANT TUBERCULOSIS. Infectious Disease Clinics of North America, 1998, 12, 157-172.	5.1	35
172	The Epidemiology of Tuberculosis in San Francisco – A Population-Based Study Using Conventional and Molecular Methods. New England Journal of Medicine, 1994, 330, 1703-1709.	27.0	1,070
173	An Outbreak of Tuberculosis with Accelerated Progression among Persons Infected with the Human Immunodeficiency Virus. New England Journal of Medicine, 1992, 326, 231-235.	27.0	978
174	The Runny Nose. Infectious Disease Clinics of North America, 1988, 2, 131-148.	5.1	16
175	Adjuvant therapy of bacterial meningitis. Pediatric Infectious Disease Journal, 1987, 6, 1160-1161.	2.0	0
176	Adjuvant therapy of bacterial meningitis. Pediatric Infectious Disease Journal, 1987, 6, 1160-1161.	2.0	1
177	<i>Mycobacterium avium</i> Complex Disease. , 0, , 663-701.		3